Literature DB >> 9011473

Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

H L Tillmann1, M P Manns.   

Abstract

Since the discovery of the hepatitis C virus (HCV), it has become evident that this infectious agent is a primary cause of posttransfusion and sporadic non-A, non-B hepatitis. Identification and introduction of surrogate markers for posttransfusion hepatitis and later introduction of anti-HCV screening has decreased the incidence of posttransfusion hepatitis. Community-acquired HCV infection is less common than posttransfusion HCV hepatitis. HCV infection may lead to liver cirrhosis without prior evidence of laboratory or histologic infection. Populations at risk for HCV infection include patients receiving organ transplants, health care workers, infants born to HCV-infected mothers, and hemodialysis patients. Intravenous drug abusers and their sexual partners also demonstrate a high rate of HCV infection. Nosocomial HCV transmission may occur despite the observance of universal precautions. Dental or surgical intervention, salivary inoculation, family members infected with HCV, cocaine abuse, HIV infection, and lower socioeconomic status also each correlate with an increased risk of infection. HCV infection is associated with many immune-mediated diseases. There may also be some relationship between human leukocyte antigens and HCV infection. Since there currently is no HCV vaccine, prevention of exposure remains the only possibility for reducing HCV transmission and prevalence.

Entities:  

Mesh:

Year:  1996        PMID: 9011473     DOI: 10.1007/bf02087874

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  202 in total

Review 1.  Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis.

Authors:  Q L Choo; A J Weiner; L R Overby; G Kuo; M Houghton; D W Bradley
Journal:  Br Med Bull       Date:  1990-04       Impact factor: 4.291

2.  Passive immunisation against hepatitis C infection.

Authors:  L D Moaven; S A Locarnini; P Schiff
Journal:  Med J Aust       Date:  1993-03-01       Impact factor: 7.738

3.  Hepatitis C infection and membranoproliferative glomerulonephritis.

Authors:  J M Doutrelepont; M Adler; M Willems; P Durez; S H Yap
Journal:  Lancet       Date:  1993-01-30       Impact factor: 79.321

4.  High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy.

Authors:  A Tran; J F Quaranta; S Benzaken; V Thiers; H T Chau; P Hastier; D Regnier; G Dreyfus; C Pradier; J L Sadoul
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

5.  Is hepatitis C virus infection a trigger of porphyria cutanea tarda?

Authors:  C Herrero; A Vicente; M Bruguera; M G Ercilla; J M Barrera; J Vidal; J Terés; J M Mascaró; J Rodés
Journal:  Lancet       Date:  1993-03-27       Impact factor: 79.321

6.  Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection.

Authors:  S I Strasser; K J Watson; C S Lee; P J Coghlan; P V Desmond
Journal:  Med J Aust       Date:  1995-04-03       Impact factor: 7.738

7.  [Viral hepatitis and blood transfusion].

Authors:  J Larsen; G Hetland; K Skaug; A Maeland
Journal:  Tidsskr Nor Laegeforen       Date:  1991-03-10

Review 8.  Autoimmune hepatitis versus viral hepatitis C.

Authors:  C P Strassburg; M P Manns
Journal:  Liver       Date:  1995-10

9.  Hepatitis C virus infection in healthcare workers: risk of exposure and infection.

Authors:  B P Lanphear; C C Linnemann; C G Cannon; M M DeRonde; L Pendy; L M Kerley
Journal:  Infect Control Hosp Epidemiol       Date:  1994-12       Impact factor: 3.254

10.  Spread of bloodborne viruses among Australian prison entrants.

Authors:  N Crofts; T Stewart; P Hearne; X Y Ping; A M Breshkin; S A Locarnini
Journal:  BMJ       Date:  1995-02-04
View more
  7 in total

1.  A study on the role of the family and other risk factors in HCV transmission.

Authors:  S Brusaferro; F Barbone; P Andrian; G Brianti; L Ciccone; A Furlan; D Gnesutta; S Stel; E Zamparo; P Toniutto; P Ferroni; V Gasparini
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

2.  Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia.

Authors:  A Loviselli; A Oppo; F Velluzzi; F Atzeni; G L Mastinu; P Farci; G Orgiana; A Balestrieri; P L Cocco; S Mariotti
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

3.  Hepatitis C infection in risk groups.

Authors:  Sead Ahmetagić; Kasim Muminhodzić; Elmir Cickusić; Vildana Stojić; Jasminka Petrović; Nijaz Tihić
Journal:  Bosn J Basic Med Sci       Date:  2006-11       Impact factor: 3.363

4.  Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease.

Authors:  H L Tillmann; D F Chen; C Trautwein; V Kliem; A Grundey; A Berning-Haag; K Böker; S Kubicka; L Pastucha; W Stangel; M P Manns
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

5.  Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan.

Authors:  Eskandar Hajiani; Rahim Masjedizadeh; Jalal Hashemi; Mehrdad Azmi; Tahereh Rajabi
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

6.  Pleuro-Pulmonary Nocardiosis as Opportunistic Infection in a Patient with Chronic Hepatitis C under Combination Treatment with Pegylated Interferon, Ribavirin, and Boceprevir.

Authors:  Csilla Putz-Bankuti; Harald H Kessler; Thomas Valentin; Eva Leitner; Emina Talakic; Helmut Schoellnast; Peter Fickert; Guenter J Krejs; Rudolf E Stauber
Journal:  Case Reports Hepatol       Date:  2013-07-09

Review 7.  Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis.

Authors:  Nahid Ramezan Ghorbani; Shirin Djalalinia; Mitra Modirian; Zahra Esmaeili Abdar; Morteza Mansourian; Armita Mahdavi Gorabi; Hamid Asayesh; Hossein Ansari; Mehrdad Kazemzadeh Atoofi; Ramin Tajbakhsh; Mehdi Noroozi; Saeid Safiri; Mostafa Qorbani
Journal:  J Res Med Sci       Date:  2017-11-28       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.